拜玛林制药以48亿美元收购爱美医疗,巩固稀有疾病领域的领导地位,推动收入增长,增强财务前景。
拜玛林制药以48亿美元收购爱美医疗,巩固稀有疾病领域的领导地位,推动收入增长,增强财务前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.